激酶组表达谱改善骨髓增生异常综合征的风险分层与治疗靶向
研究评估341例成人原发性骨髓增生异常综合征(MDS)患者的激酶组表达谱,鉴定出7种激酶(PTK7、KIT、MAST4、NTRK1、PAK6、CAMK1D、PRKCZ)的表达水平可高度预测患者生存受损,并构建激酶分层评分(KISS),在2个外部MDS队列中验证其预后意义;较高的KISS与较老年龄、较高外周血和骨髓原始细胞百分比、较高修订版国际预后评分系统(IPSS-R)风险、复杂核型及MDS中若干不良风险基因突变相关;多因素分析证实较高KISS是MDS的独立不良风险因素;机制上,KISS-high患者富集与造血和白血病干细胞特征相关的基因集;通过研究癌症药物敏感性基因组学数据库,鉴定出阿昔替尼和taselisib作为可能靶向KISS-high髓母细胞的候选化合物;总之,KISS有望改善当前MDS的预后方案并提供新的治疗机会。
要点
- 7种激酶(PTK7、KIT、MAST4、NTRK1、PAK6、CAMK1D、PRKCZ)表达水平可高度预测MDS患者生存受损。
- 较高KISS与较老年龄、较高外周血和骨髓原始细胞百分比、较高IPSS-R风险、复杂核型及不良风险基因突变相关。
- 多因素分析证实较高KISS是MDS的独立不良风险因素。
核心结论
- KISS有望改善当前MDS的预后方案并提供新的治疗机会。
- 较高的KISS是MDS的独立不良风险因素。
研究设计与样本
- 研究评估341例成人原发性MDS患者的激酶组表达谱。
- 构建激酶分层评分(KISS)并在2个外部MDS队列中验证其预后意义。
- 通过研究癌症药物敏感性基因组学数据库鉴定候选化合物。
主要发现
- 鉴定出7种激酶(PTK7、KIT、MAST4、NTRK1、PAK6、CAMK1D、PRKCZ)表达水平可高度预测患者生存受损。
- 较高KISS与较老年龄、较高外周血和骨髓原始细胞百分比、较高IPSS-R风险、复杂核型及MDS中若干不良风险基因突变(如ASXL1、EZH2、NPM1、RUNX1、STAG2和TP53)相关。
- 多因素分析证实较高KISS是MDS的独立不良风险因素。
- KISS-high患者富集与造血和白血病干细胞特征相关的基因集。
- 鉴定出阿昔替尼和taselisib作为可能靶向KISS-high髓母细胞的候选化合物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The human kinome, which comprises >500 kinases, plays a critical role in regulating numerous essential cellular functions. Although the dysregulation of kinases has been observed in various human cancers, the characterization and clinical implications of kinase expressions in myelodysplastic syndromes (MDS) have not been systematically investigated. In this study, we evaluated the kinome expression profiles of 341 adult patients with primary MDS and identified 7 kinases (PTK7, KIT, MAST4, NTRK1, PAK6, CAMK1D, and PRKCZ) whose expression levels were highly predictive of compromised patient survival. We then constructed the kinase stratification score (KISS) by combining the weighted expressions of the 7 kinases and validated its prognostic significance in 2 external MDS cohorts. A higher KISS was associated with older age, higher peripheral blood and marrow blast percentages, higher Revised International Prognostic Scoring System (IPSS-R) risks, complex karyotype, and mutations in several adverse-risk genes in MDS, such as ASXL1, EZH2, NPM1, RUNX1, STAG2, and TP53. Multivariate analysis confirmed that a higher KISS was an independent unfavorable risk factor in MDS. Mechanistically, the KISS-high patients were enriched for gene sets associated with hematopoietic and leukemic stem cell signatures. By investigating the Genomics of Drug Sensitivity in Cancer database, we identified axitinib and taselisib as candidate compounds that could potentially target the KISS-high myeloblasts. Altogether, our findings suggest that KISS holds the potential to improve the current prognostic scheme of MDS and inform novel therapeutic opportunities.
引用
- Yao CY, Lin CC, Wang YH, et al. Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes. Blood Adv. 2024. PMID: 38527292. doi:10.1182/bloodadvances.2023011512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。